(IN BRIEF) AstraZeneca and Quell Therapeutics have announced a collaboration to develop innovative treatments for Type 1 Diabetes and Inflammatory Bowel Disease. Quell’s T-regulatory cell engineering technology will be used to create potential curative therapies. AstraZeneca has the option to … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, United Kingdom
Tagged AstraZeneca, autoimmune disease, cell therapies, Foxp3 Phenotype Lock, Iain McGill, IBD, IND, inflammatory bowel disease, Investigational New Drug, Mene Pangalos, multi-modular Treg cell therapy, Quell, Quell Therapeutics, T-regulator, T-regulatory cell engineering, T1D, Treg, type 1 diabetes
(IN BRIEF) Novo Nordisk has announced a collaboration with Aspect Biosystems to develop bioprinted tissue therapeutics for diabetes and obesity treatment. The collaboration will leverage Aspect’s bioprinting technology and Novo Nordisk’s expertise in stem cell differentiation and cell therapy development … Read the full press release
(IN BRIEF) Sanofi has agreed to acquire Provention Bio, a U.S.-based biopharmaceutical company focused on preventing and intercepting immune-mediated diseases, for $2.9 billion. The acquisition includes Provention Bio’s first-in-class therapy for type 1 diabetes, TZIELD, which was approved in the … Read the full press release
4 million1 hours of hypoglycemia avoided Trust in the algorithm leads to fewer meal declarations Users report a significantly reduced mental load (PRESS RELEASE) PARIS, 21-Sep-2022 — /EuropaWire/ — Diabeloop, a leader in therapeutic AI applied to insulin delivery, reports … Read the full press release
Posted in Denmark, France, Healthcare, News, Pharma & Biotech, Science, Sweden, Technology
Tagged #dedoc, automated insulin delivery, DBL-4pen, DBL-hu, DBLG1, Diabeloop, Diabetes, EASD, EASD Annual Meeting 2022, EASD2022, Erik Huneker, hybrid closed-loop system, Hypoglycemia, insulin delivery, Pr. Lutz Heinemann, Pr. Pierre-Yves Benhamou, Stéphanie JEGU, therapeutic AI, Time In Range, type 1 diabetes
High-growth diabetes company Diabeloop closes its Series C financing round – led by LBO France, joined by Terumo Corporation, Innovacom and backed by Diabeloop’s historical partners – to power the company’s commercial roll-out and global expansion. (PRESS RELEASE) PARIS, 2-Jun-2022 … Read the full press release
Posted in Artificial Intelligence (AI), Denmark, Financial, France, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged AGIR A DOM., AI, automated insulin delivery, Catherine Dunand, CEMAG invest, CERITD, CGM, Continuous Glucose Monitoring device, Credit Agricole, DBL-hu, DBLG1, DBLG1 System, Diabeloop, Diabetes, Erik Huneker, financing round, Hikaru Samejima, Innovacom, insulin, Kreaxi, LBO France, ML software for diabetes treatment, Odyssée Venture, Promontoires, Series C, Series C financing round, Sofimac, Stéphanie JEGU, Supernova Invest, T1D, Terumo, Terumo Corporation, therapeutic AI, therapeutic artificial intelligence, type 1 diabetes, UI Investissement, Valery Huot
(PRESS RELEASE) PARIS, 28-Apr-2022 — /EuropaWire/ — ATTD 2022 – Diabeloop, pioneer in therapeutic artificial intelligence for diabetes management, presents today new results from a real-life cohort in Germany. The data show a constant improvement in Time In Range (70-180 … Read the full press release
Posted in Artificial Intelligence (AI), Denmark, France, Healthcare, News, Pharma & Biotech, Science, Spain, Technology
Tagged Accu-Chek Insight, AI, aid, artificial-intelligence, ATTD 2022, automated insulin delivery, biphasic boluses, blood sugar level, DBL-hu, DBLG1, DBLG1 iController, DBLG1 System, Diabeloop, Diabetes, diabetes management, Erik Huneker, glucose control, glycemic control, HbA1c, Insulin Pump, postprandial hyperglycemia, Prof. Pierre-Yves Benhamou, real-life DBLG1 cohort, reduction of hypoglycemia, reduction of hypoglycemic episodes, Roche, Stéphanie JEGU, T1D, Time In Range, TIR, type 1 diabetes, WP7, WP72 study, YourLoops
(PRESS RELEASE) PARIS, 12-Apr-2022 — /EuropaWire/ — Diabeloop, a pioneer in the field of therapeutic artificial intelligence, leverages the potential of its diabetes technology to enable the integration of insulin pens into its hybrid closed-loop system using a unique app. … Read the full press release
Posted in Denmark, France, Healthcare, News, Pharma & Biotech, Spain, Technology
Tagged aid, automated insulin delivery, BIOCORP, DBL-4pen, DBL-hu, DBLG1, Diabeloop, Diabetes, Erik Huneker, insulin pen, insulin therapy, Mallya®, Marc Julien, multiple daily insulin injections, Prof. Hélène Hanaire, Seagrove Partners, Simon-Kucher, smart pen, Stéphanie JEGU, therapeutic AI, type 1 diabetes, type 2 diabetes, University Hospital of Toulouse, YourLoops
EASD 2021 – Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, is presenting new real-world data(1) of its Automated Insulin Delivery system, DBLG1. The personalized device fine-tunes insulin delivery using a state-of-the-art algorithm. Thousands of European patients have … Read the full press release
Posted in Artificial Intelligence (AI), France, Healthcare, Italy, News, Pharma & Biotech, Science, Spain, Technology
Tagged ACCU-CHEK, Accu-Chek Insight, algorithm, artificial-intelligence, Automated Insulin Delivery system, CE certificate, CGM, continuous glucose monitor, data, data visualization platform, DBLG1, DBLG1 System, Dexcom, Dexcom G6, Diabeloop, Diabetes, EASD 2021, Erik Huneker, glucose, HbA1c, Hypoglycemia, Insulin Pump, Pr. Pierre-Yves Benhamou, Roche, Stéphanie JEGU, T1D, therapeutic artificial intelligence, therapeutic artificial intelligence for diabetes management, Time In Range, TÜV Rheinland, type 1 diabetes, YourLoops
BIRMINGHAM, 22-4-2015 — /EuropaWire/ — Researchers from the University of Birmingham have identified an important new way in which our immune systems are regulated, and hope that understanding it will help tackle the debilitating effects of type 1 diabetes, rheumatoid … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
